ENDRA Life Sciences Inc. (NDRA): Entry into a Material Definitive Agreement
ENDRA Life Sciences Inc. (NDRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029523901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JUNE 25, 2026, BY AND AMONG ENDRA LIFE SCIENCES INC., KRUGER MERGER SUB LLC, RENERGEN LIMITED, NOBLE AFRICA LLC AND ASP ISOTOPES INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ASP ISOTOPES INC., NO
How this was made
The 30-second read
Why it matters
This is a deal-structure disclosure that can change expected cash/stock outcomes, voting dynamics, and deal-spread behavior; the excerpt does not provide the purchase price or final exchange ratio.
Market read
Deal-spread and event-risk trading is likely to increase for NDRA as the company moves from announcement to definitive agreement and toward proxy/closing milestones.
What to watch
Traders should watch for the proxy/registration statement, Nasdaq listing compliance steps (reverse split), and any financing/closing conditions that could delay or derail the deal.
Background
The 8-K states ENDRA Life Sciences entered a material definitive agreement (Agreement and Plan of Merger) dated June 25, 2026, involving a parent/sub structure and a reverse stock split to maintain Nasdaq compliance.
Ticker impact
ENDRA filed an 8-K disclosing it entered a material definitive merger agreement dated June 25, 2026.
Near-term volatility likely around deal headlines, proxy/registration milestones, and any financing/regulatory or closing-condition updates.
The article is a primary SEC 8-K entry into a merger agreement; however, the excerpt does not include deal economics (consideration, structure, or timeline), limiting precision on magnitude.
Market effects
Could modestly affect sentiment for small-cap life-sciences/diagnostics M&A activity, but no sector-wide datapoints are provided here.
Limited; the transaction is company-specific with no broader regional macro/regulatory trigger described.
Limited; the excerpt references a South Africa subsidiary but provides no cross-border regulatory or market-wide catalyst.
Counterpoint
A definitive agreement can still face termination risk; without disclosed consideration and conditions, the market may overprice the probability of closing.
Key entities
- public_companyENDRA Life Sciences Inc.
Nasdaq-listed company (NDRA) that entered the material definitive merger agreement disclosed in the 8-K.
- public_companyASP Isotopes Inc.
Named as Parent in the merger agreement; will contribute equity interests into an intermediate holding company structure.
- entityKruger Merger Sub LLC
Merger Sub formed as a wholly-owned subsidiary of PubCo and party to the merger agreement.
- entityRenergen Limited
Named OpCo subsidiary of Parent in the merger agreement.
